Overview

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAK

Status:
Completed

Trial end date:
2017-11-27

Target enrollment:

Participant gender:

Summary

The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program.

Phase:

Phase 3

Details

Lead Sponsor:

Santen Inc.

Treatments:

Everolimus
Sirolimus